by Rod Raynovich | Jul 16, 2011 | BIOgraph, Life Science ETF's and Mutual Funds
Edited Version Published in Investor Uprising June 2011 :Updated here JY 16, 2011 Biotechnology Has Outperformed the S&P Over Five Years Medical science has always been an important area for investors and recent breakthroughs with new drugs and devices have...
by Rod Raynovich | Jul 15, 2011 | BIOgraph, Macro
Large cap drug and biotech stocks sold off as buyers favor technology. Within the NASDAQ-100 up 1% led by GOOG, BIDU and SIRI. Alexion (ALXN $52.19) bucked the weakness in biotech up 1.74% but GILD, ILMN and AMGN down. Some major rotation going on today out of...
by Rod Raynovich | Jul 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph, Reading List
Life Science Sector Outperforms NASDAQ-100: Movers are ROSGD, VICL Biotechnology stocks sold off about 0.65% overall as industry news and fundamentals were eclipsed by MACRO issues. Concerns loom about European debt, US debt ceiling and potential default. JPMorgan...
by Rod Raynovich | Jul 12, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Life Science Stocks are Stable in a Choppy Market; Macro Is Dominating The NASDAQ market stabilized today (but down 0.54%) after a two day sell-off that brought the qqq down to $57.79 from the $59.50 level last Thursday.The market skittishness was primarily caused by...
by Rod Raynovich | Jul 8, 2011 | BIOgraph, Reading List
A front page article in the New York Times today by Gina Kolata, “How Bright Promise in Cancer Testing Fell Apart”, chronicles a patient case study at Duke University about gene based tests for lung cancer. Additional commentary at other research...
by Rod Raynovich | Jul 6, 2011 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
Diagnostics is Still a Hot Ticket The Rayno Life Science Tools and Diagnostics Portfolio is up 12% YTD with big winners Celera up 31%, recently acquired by Quest Diagnostics (DGX), Cardiovascular Systems (CSII) up 32.5%,Exact Scientific (EXAS) up 42%, and GenProbe...
by Rod Raynovich | Jul 4, 2011 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
2011 A Huge Year for Life Science Investing As of mid-year the Rayno Life Science Biopharmaceutical Portfolio was up over 20% beating most ETF’s and Life Science mutual funds. Our two recommended biotech ETF’s for balancing and overweighting were FBT up...
by Rod Raynovich | Jun 30, 2011 | BIOgraph
The 2011 Bio Meeting was well attended surpassing last year’s number around 15,000. International participation continues to grow with 37% of attendees outside of the U.S. Virtually every country that has industry and universities is looking at biotech...
by Rod Raynovich | Jun 26, 2011 | 2024-25 Life Science Portfolios, BIOgraph
We will be attending the BIO Meeting in Washington DC and will not be posting as usual. Note that there were two news items over the weekend on our portfolio stocks: A positive article on Gilead (GILD) in Barron’s. Gilead Sciences Shares Could Rally –...
by Rod Raynovich | Jun 23, 2011 | BIOgraph, Macro
Techs and Biotechs Turn Around Its up- its down- its way down -its coming back.At the end of the day NASDAQ recovered up 0.66% after being down more than 1.4%, the Dow was down 0.49% and the S&P down o.28%. Crosscurrents were too numerous to cover: plunge in oil...
